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S U M M A R Y
Background: A. baumannii is an important nosocomial pathogen associated with high mortality,
morbidity and medical cost.
Aim: The aim of this study was to investigate risk factors for MDR A. baumannii bacteremia and also
evaluate cost of hospitalization of these patients.
Methods: Study was conducted in Ankara Atatu¨rk Training and Research Hospital. Patients who were
hospitalized in ICU and diagnosed for nosocomial blood stream infection (BSI) between January 2007 and
December 2010 were checked retrospectively. Patients with nosocomial BSI caused by multidrug
resistant A. baumannii were compared with the patients who had BSI caused by other Gram-negative
microorganisms in terms of risk factors, mortality and medical costs.
Findings: In multivariate analysis previous use of carbapenem, quinolone and metronidazole, and SAPS II
score were found as independent risk factors. In case group; immunosupression, SAPS II score, and
hospital stay until infection were independently associated with mortality in multivariate analysis.
Conclusion: Our results suggest that the occurrence of MDR A.baumannii bacteremia was related with the
usage of the wide spectrum antibiotics, and mortality rates were increased in patients that high SAPS II
scores, long term hospitalization. Infection control procedures and limited antibiotic usage are very
important for prevent nosocomial infections.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hospital acquired infections are leading causes of morbidity
and mortality due to increasing rate of antibiotic resistance.
Especially, patients followed in the intensive care units (ICU) are
under high risk of infections caused by resistant microorganisms.1
Rapid development and global spread of A. baumannii as a major
cause of nosocomial infections is really remarkable. This organism
tends to develop resistance against many antimicrobials from
different groups.2,3 In the 21st century, A. baumannii is frequently
observed as a nosocomial infection which causes high mortality,
morbidity and hospitalization cost.4,5 Crude mortality rate and
attributable mortality of the infection were reported to be 52% and
10-35%, respectively.6* Corresponding author. Nigde State Hospital, Nigde,Turkey.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The aim of this study was to explore the risk factors in patients
with multi-drug resistant (MDR) A. baumannii bacteremia and
perform a cost analysis of this clinical problem.
2. Material and Methods
This retrospective cohort study has included the patients who
had nosocomial blood stream infections (BSI) caused by MDR A.
baumannii and hospitalized in General Intensive Care (GICU) and
Neurology-Neurosurgery Intensive Care (NNICU) Units of Ankara
Atatu¨rk Training and Research Hospital between 01 January 2007 –
31 December 2010.
2.1. Patients
Forty-one patients with diagnosis of nosocomial BSI and MDR A.
baumannii detected in the blood culture were enrolled as the
patient group. Forty-ﬁve patients who were hospitalised in theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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positive blood cultures for Gram-negative microorganisms other
than A. baumannii were accepted as control group. Patient
characteristics were retrospectively scanned and recorded to
study forms.
2.2. Deﬁnitions
When a patient had at least one of the clinical ﬁndings of fever
(38.0 8C), chills or hypotension at least 48 hours after hospitaliza-
tion, A. baumannii was isolated in at least one of the blood cultures
obtained from a peripheral vein or central catheter and no A.
baumannii was isolated in any other culture related with other
sources of infection, then diagnosis of bacteremia was accepted.
Catheter related BSI was considered as primary BSI. A. baumannii
isolation in blood culture secondary to any other source of
infection was considered as secondary BSI.
Multi-drug resistance was deﬁned as the resistance of A.
baumannii isolates in  3 antimicrobial category to 1 agent from
antimicrobial groups aminoglycosides, anti-pseudomonal penicil-
lins + beta lactamase inhibitors, extended spectrum cephalospor-
ins, folate pathway inhibitors, penicillins and inhibitors and
polymyxin group antimicrobials.
Septic shock was deﬁned as the sepsis state in which persistant
hypotension despite ﬂuid replacement (average arterial pressure
70 mmHg), organ dysfunction and perfusion abnormalities are
observed.
Immunosuppression was deﬁned as presence of corticosteroid
treatment equivalent to at least 10 mg/day prednisolone for ﬁfteen
days, human immunodeﬁciency virus (HIV) seropositivity, solid
organ transplantation, bone marrow transplantation, history of
radiotherapy or chemotherapy for an underlying malignancy in
last 6 months and presence of acquired immune deﬁciencies
(hypogammaglobulinemia, combined immunodeﬁciency syn-
drome).
Previous antimicrobial usage was deﬁned as systemic antimi-
crobial treatment for at least 72 hours in 30 days before isolation of
Gram-negative microorganism in blood culture.
2.3. Microbiological Analysis
Blood cultures were incubated in BACTEC 9050 system and
were identiﬁed by BD BBL Crystal identiﬁcation system. Antimi-
crobial susceptibility proﬁles were determined by Kirby Bauer Disc
Diffusion Method in accordance with Clinical and Laboratory
Standarts Institute (CLSI) recommendations.7 Due to increase in
resistance against antimicrobials like cephoperazone sulbactam
and netilmisin, colistin susceptibility test also has been added to
the proﬁle since, 2010 thus colistin susceptibility was also
evaluated in 7 isolates which were isolated in 2010.
2.4. Cost Analysis
Total hospitalization cost was determined by using the central
hospital information system and recorded both case and control
group patients. Unit cost of antimicrobial agents that were used
during bacteremia episode was acquired from hospital purchase
department and cost of antimicrobial therapy and hospitalization
were calculated in American Dollars(US$).
2.5. Statistical Method
SPSS 15.0 for Windows was used for statistical analysis of the
data. The table of numbers was presented for categoric variables
while deﬁnitive statistics (mean, standart deviation, median,
minimum, maximum) were presented for numerical variables.In order to make paired categorical comparisons, Chi square test
was used for independent groups with normal distribution while
Fisher’s exact test was used for independent groups with no
normal distribution. For numerical comparions, t test was used in
independent groups with normal distribution while Mann
Whitney U test was used in independent groups without normal
distribution. Regression analysis of infection and mortality related
risk factors was performed by using Forward-Stepwise method.
Kaplan Meier test was also used for survival analysis and
Backward-stepwise, forward stepwise methods and cox regression
analysis were used to determine the risk factors affecting survival
rate. A p value less than 0.05 was accepted to be statistically
signiﬁcant.
3. Results
In this study, case group was comprised of 41 patients (23 female,
18 male), of which the mean age was 58.3  21.9 years while the
control group had 45 patients (16 female, 29 male) whose mean age
was 60.6  20.5 years.
When the case group was evaluated, the percentages of patients
in case and control groups with concomitant MDR A. baumannii
infection other than BSI were 78% and 34%, respectively.
Univariate analysis revealed that the presence of an arterial
catheter, high SAPS II score, low serum albumin level, antibiotic
treatment with carbapenem, quinolone, metronidazole, glycopep-
tides and aminoglycosides prior to BSI were the risk factors for
MDR A. baumannii BSI (Table 1, Table 2).
In multivariate analysis, it was detected that antibiotic
treatment with carbapenem (odds ratio (OR) 11.96; 95% conﬁ-
dence interval(CI) 3.31- 43.3; p < 0.001), quinolone (OR 6.71; 95%
CI 1.31 – 34.40; p = 0.02), metronidazole (OR 1.06; 95% CI 2.59 –
391.22; p = 0.007) prior to diagnosis of MDR Acinetobacter BSI and
SAPS II score (OR 1.06; CI 1.01 – 1.11; p = 0.1) were the
independent risk factors for MDR A. baumannii infection (Table 3).
Crude mortality rate in the case group was 53.7% while 14-day
and 28-day mortality rates were 52.4% and 30%, respectively.
Mortality attributed to A. baumannii BSI was detected as 24.4%.
Mean age of patients who died, immunosuppression rates and
SAPS II scores were statistically high in univariate analysis
(p < 0.001, p = 0.02, p = 0.001, respectively) (Table 4). In multivar-
iate analysis, immunosuppression (OR 4.67; CI 1.19 – 18.36;
p = 0.02), SAPS II score (OR 0.1.10; CI 1.09 – 1.16; p < 0.001),
hospitalization stay until BSI (OR 0.95; CI 0.92 – 0.98; p = 0.001)
were determined as independent risk factors (Table 4).
The mean hospitalization costs of patients in case and control
groups were calculated as US$35277  US$31758 and
US$26333  US$20398, respectively and no signiﬁcant difference
was detected between them (p = 0.282). Mean costs of antibiotics
were calculated for alive patient from each group and were
US$1052  US$613 and US$836  US$567 for case and control
groups, respectively. There was no signiﬁcant difference between
the two groups with respect to the cost of antibiotics (p = 0.249).
4. Discussion
Nosocomial A. baumannii infections are frequently observed
especially in intensive care units. Besides being resistant to many
antimicrobial agents, this microorganism also has the potential to
develop resistance against many antimicrobials during treatment
via new mechanisms. In many studies, it was shown that incidence
of nosocomial infections caused by MDR A. baumannii is increasing
worldwide.8–11
This study assessed the risk factors for the development of MDR
A. baumannii BSI, mortality related factors, and cost of this clinical
picture. Risk factors for MDR A. baumannii implicate variables
Table 1
Demographic characteristics of the patients
Patient
n = 41
Control
n = 45
p
Gender (n,%)
Female 23 (56.1) 16 (35.6) 0.056
Male 18 (43.9) 29 (64.4)
Age (MeanStd. Dev.) 58.3  21.9 60.6  20.5 0.659
Clinic (n, %)
GICU 27 (65.9) 30 (66.7) 0.937
NICU 14 (34.1) 15 (33.3)
Bacteremia (n, %)
Primary 24 (58.5) 24 (53.3) 0.627
Secondary 17 (41.5) 21 (46.7)
Diabetes Mellitus (n, %) 10 (24.4) 14 (31.1) 0.488
Chronic Renal Failure (n, %) 4 (9.8) 4 (8.9) 1.000
Heart Failure (n, %) 10 (24.4) 7 (15.6) 0.304
Malignity (n, %) 1 (2.4) 5 (11.1) 0.205
Chronic Obstructive
Pulmonary Disease (n, %)
7 (17.1) 10 (22.2) 0.549
Acute Respiratory Distress
Syndrome (n, %)
6 (14.6) 6 (13.3) 0.862
Immunosuppression (n, %) 6 (14.6) 6 (13.3) 0.862
Mechanical ventilation
(MV)(n, %)
34 (82.9) 39 (86.,7) 0.629
Central Vein catheterization
(CVC)(n, %)
39 (95.1) 40 (88.9) 0.437
Arterial catheterization
(AC)(n, %)
30 (73.2) 21 (46.7) 0.01
Peripheral Venous
Catheterization (n, %)
4 (9.8) 6 (13.3) 0.741
Total Parenteral
Nutrition (n, %)
22 (53.7) 26 (57.8) 0.701
Nasogastric tube (n, %) 18 (43.9) 18 (40.0) 0.714
Urinary catheter (n, %) 41 (100.0) 44 (97.8) 1.000
Hospitalization time
before BSI(Mean  Std.Dev.)
25.49  21.47 22.80  19.28 0.429
CVC day before BSI (n, %) 17.02  17.04 18.40  16.51 0.700
MV day before BSI (n, %) 17.24  17.68 19.69  20.20 0.879
Septic shock (n, %) 12 (29.3) 6 (13.3) 007
Prior surgical operation (n, %) 16 (39.0) 14 (31.1) 0.442
SAPS II (Mean  Std.Dev) 55.20  14.4 48.4  12.4 0.02
Albumin (Mean  Std.Dev) 2.70  0.45 2.85  0.33 0.02
Creatinin (Mean  Std.Dev) 1.30  1.00 1.54  1.46 0.652
Proper empirical treatment
(n, %)
13 (31.7) 4 (8.9) 0.008
Table 2
Antibiotics used before BSI was diagnosed
Antibiotics Patient (n,%)
(n = 41)
Control (n,%)
(n = 45)
p value
Carbapenem 23 (56.1) 7 (15.6) <0.001
3rd generation cephalosporin 22 (53.7) 19 (42.2) 0.289
Aminoglycoside 22 (53.7) 9 (20.0) 0.001
Glicopeptide 15 (36.6) 7 (15.6) 0.02
Piperacillin tazobactam 14 (34.1) 10 (22.2) 0.218
First generation cephalosporin 9 (22.0) 13 (28.9) 0.461
Quinolone 9 (22.0) 3 (6.7) 0.04
Metronidazole 8 (19.5) 1 (2.2) 0.01
Sulbactam-ampicillin 7 (17.1) 11 (24.4) 0.401
Linezolide 3 (7.3) 4 (8.9) 1.000
Table 4
Mortality related risk factors determined in the case group by regression analysis
P OR %95 CI
Immunosupression 0.02 4.67 1.19 18.36
SAPS II <0.001 1.10 1.04 1.16
Hospitalisation time prior to BSI 0.001 0.95 0.92 0.98
OD: Odds ratio, CI: Conﬁdence interval.
Table 3
Risk factors which are estimated by regression analysis for multi drug resistant A.
baumannii bacteremia
P OR %95 CI
Carbapenem <0.001 11.96 3.31 43.30
Quinolone 0.02 6.71 1.31 34.40
Metronidazole 0.007 31.85 2.59 391.22
SAPS II 0.01 1.06 1.01 1.11
OR: Odds ratio, CI: Conﬁdence interval.
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measures, underlying disease, exposure to antibiotics. The factors
in our patient grup include high SAPS II score, low serum albumin
level, previous antibiotic therapy including carbapenem, amino-
glycosides, glycopeptides, quinolone and metronidazole, arteriel
catheterization.
Several investigators have found a relationship between multi-
drug resistance and invasive procedures. In these studies it was
shown that invasive mechanical ventilation, central venous
catheterization, urinary catheterization and nasogastric tube is a
risk factor for multi-drug resistance.12–15 In contrast, in our study,
arterial catheter was determined as a risk factor among invasive
procedures. It gives rise to thought the difference of risk factors
between different studies may be related with the inter-institutional
difference in the compliance to infection control precautions.
It is known that in order to start early, proper antibiotic
treatment is very important in ICUs. In two studies, authors
showed that the percentage of proper antimicrobial treatment was
much lower in patients with MDR A. baumannii infection.16,17 In
our study, proper empirical antibiotic treatment rate was
signiﬁcantly high for patients in A. baumannii bacteremia arm
(p = 0.018). The presence of the same pathogen as infection agent
in more than one patient in a ward may affect the choice of
empirical treatment, it may be possible that empirical treatment
might be started in our study population by taking a possible MDR
A. baumannii into account.
One of the most important factor underlying antimicrobial
resistance of A. baumannii infections is long term treatment of the
infection with a broad spectrum antibiotics. Our results showed
that prior antibiotic treatment by using carbapenem, quinolone,
aminoglycoside, glycopeptide and metronidazole is a risk factor for
MDR A. baumannii bacteremia. This result was compatible with
other studies.5,18–21 In order to prevent development of resistance
aganist antimicrobials, these agents must be used for right
therapeutic indications for a suitable treatment period.
In multivariate analysis, antibiotic treatment with carbapenem,
quinolone, metronidazole prior to bacteremia and SAPS II score
were found to be independent risk factors. When literature was
searched, it was observed that, in a clinical study which was
performed in our country and in which imipenem susceptible and
resistant A. baumannii infections were compared, hospitalization
time prior to infection and prior antibiotic usage were identiﬁed as
risk factors.12 In another study, A. baumannii colonization and
bacteremia were compared and regression analysis revealed that
respiratory failure, presence of a central venous catheter, antibiotic
usage prior to infection were independent risk factors.10 Another
study in which bacteremias caused by A. baumanni and by other
causative agents were compared showed that immunosuppres-
sion, hospitalization through emergency unit, respiratory failure
during hospitalization, prior antibiotic agent consumptions were
independent risk factors.13
Crude mortality rate for infections caused by MDR A. baumannii
is high and different percentages are reported (26-58%) in the
literature.22,23 Besides studies reporting that A. baumannii itself
increases the mortality, however, there are some studies which
claim that mortality increase is mostly related with underlying
disease and A. baumannii infection, itself is not an independent risk
T.A. Gulen et al. / International Journal of Infectious Diseases 38 (2015) 32–35 35factor which affects mortality rate.14,24,25 Crude mortality rate for
our case patient group was 53%. No statistically signiﬁcant
difference between case and control groups were detected for
14-day and 28-day mortality rates. This situation is claimed to be
related with high rate of proper empirical antimicrobial therapy in
our case group. In our study, immunosuppression, SAPS II score and
hospitalization prior to BSI were deﬁned as independent risk
factors for mortality. Immunosuppression was a risk factor for
mortality in our case group and it was observed that survival rates
were statistically lower in immunosuppressive patients. Besides
increasing the mortality, immunosuppression has also a negative
effect on survival rate, as well.
Studies focusing on cost effectiveness analysis of A. baumannii
bacteremia are very rare and these studies show that cost of this
infection is much higher. In one of these studies, Lee et. al. ﬁgured
out that mean hospitalization cost and cost of antibiotics were
higher in infections caused by resistant A. baumannii.14 The
comparative cost analysis of MDR A. baumannii bacteremia and
bacteremias caused by other Gram-negative agents revealed no
signiﬁcant differences in total hospitalization cost and cost of
antibiotics. As mentioned before, this result was related with
choice of control group patients in prior study from susceptible
bacteremia patients. In a review, it was shown that hospital costs
attributable to multi-drug resistance are alarmingly high.26
Finally, patients in ICU are under great risk of resistant
nosocomial infections. When risk factors for multidrug resistance
which were evaluated in our study are considered, it is obvious
that some of these can be preventable. The decision for invasive
procedures and necessity of invasive equipments must be decided
on the basis of individual patient so that unnecessary practices can
be avoided. Proper antimicrobial agent must be used for an
optimum period and care must be given to prevent unnecessary
antibiotic usage. It is important to treat infection with a proper
antibiotic as soon as possible, especially in infections caused by
MDR microorganisms and in which treatment options are limited.
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